Stock Analysis on Net
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Analysis of Liquidity Ratios
Quarterly Data

Beginner level

Liquidity Ratios (Summary)

Vertex Pharmaceuticals Inc., liquidity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Current ratio 3.72 3.54 3.61 3.44 3.74 3.78 3.43 3.71 3.67 3.68 3.28 3.28 3.49 3.82 2.31 2.08 2.33 2.54 2.78 3.63 3.46 4.49
Quick ratio 3.47 3.27 3.33 3.20 3.51 3.54 3.19 3.46 3.41 3.39 2.94 2.92 3.06 3.30 2.06 1.81 2.02 2.19 2.41 3.12 2.97 4.17
Cash ratio 3.03 2.72 2.85 2.88 3.14 3.14 2.83 3.08 2.98 2.99 2.59 2.55 2.67 2.88 1.81 1.56 1.72 1.86 2.06 2.68 2.72 3.91

Based on: 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-08-01), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-13), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-10-30), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-10-31), 10-Q (filing date: 2016-08-01), 10-Q (filing date: 2016-05-03), 10-K (filing date: 2016-02-16), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-04).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Vertex Pharmaceuticals Inc.’s current ratio deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Vertex Pharmaceuticals Inc.’s quick ratio deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Vertex Pharmaceuticals Inc.’s cash ratio deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level.

Current Ratio

Vertex Pharmaceuticals Inc., current ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Current assets 6,694,320  5,446,400  4,822,829  4,777,094  4,710,968  4,183,039  3,843,109  3,686,611  3,407,423  3,041,116  2,648,963  2,327,974  2,180,572  1,871,814  1,831,540  1,501,901  1,454,150  1,402,835  1,407,153  1,359,452  1,294,689  1,358,203 
Current liabilities 1,798,640  1,538,750  1,334,827  1,388,894  1,259,220  1,106,468  1,120,292  992,508  927,300  827,312  807,260  710,739  625,406  489,796  792,537  722,841  622,855  552,041  506,349  374,959  373,823  302,438 
Liquidity Ratio
Current ratio1 3.72 3.54 3.61 3.44 3.74 3.78 3.43 3.71 3.67 3.68 3.28 3.28 3.49 3.82 2.31 2.08 2.33 2.54 2.78 3.63 3.46 4.49
Benchmarks
Current Ratio, Competitors2
Abbott Laboratories 1.57 1.43 1.44 1.54 1.68 1.58 1.62 1.42 1.58 1.66 2.26 2.69 2.94 2.91 4.02 1.56 1.50 1.48 1.54 1.82 2.30 2.17
AbbVie Inc. 0.86 3.14 3.18 1.15 0.89 1.04 0.98 1.20 0.80 1.20 1.28 1.45 1.38 1.76 1.65 1.79 1.81 1.56 1.50 2.03 1.50 1.39
Amgen Inc. 2.18 1.59 1.44 2.89 2.89 2.77 2.79 3.08 3.39 3.88 5.49 6.07 6.20 4.41 4.11 4.35 3.97 4.95 4.44 5.42 5.48 5.53
Biogen Inc. 2.46 1.73 1.72 1.91 2.46 2.84 2.32 2.75 2.36 3.23 2.34 2.19 2.10 2.29 2.55 3.24 2.96 2.59 2.60 3.52 2.20 2.70
Bristol-Myers Squibb Co. 1.47 1.66 1.60 3.83 3.88 1.93 1.61 1.53 1.40 1.52 1.55 1.59 1.59 1.60 1.55 1.47 1.56 1.48 1.30 1.81 1.76 1.94
Eli Lilly & Co. 1.22 1.11 1.16 1.17 1.13 1.12 1.73 1.91 1.40 1.41 1.32 1.38 1.39 1.24 1.37 1.62 1.54 1.60 1.53 1.51 1.50 1.41
Gilead Sciences Inc. 2.33 3.04 3.10 2.96 3.76 3.62 3.38 3.45 3.00 2.84 2.74 3.68 3.37 2.59 2.22 1.93 1.76 1.77 2.50 2.77 2.03 2.70
Illumina Inc. 3.76 4.10 6.69 6.82 6.79 3.66 2.49 2.46 2.74 2.71 3.99 4.22 3.88 3.49 3.29 3.62 3.69 4.31 3.43 3.79 3.09 2.90
Johnson & Johnson 1.25 1.31 1.26 1.26 1.33 1.44 1.47 1.72 1.65 1.58 1.41 1.32 1.34 2.52 2.47 2.73 3.08 2.83 2.17 2.51 2.49 2.44
Merck & Co. Inc. 1.32 1.11 1.24 1.26 1.21 1.37 1.17 1.44 1.33 1.42 1.33 1.43 1.50 1.59 1.78 1.89 1.87 1.64 1.55 1.62 1.62 1.61
Pfizer Inc. 1.42 1.03 0.88 0.90 1.47 1.54 1.57 1.43 1.16 1.27 1.35 1.43 1.34 1.44 1.25 1.11 1.37 1.44 1.49 1.62 2.14 2.45
Regeneron Pharmaceuticals Inc. 2.12 4.21 3.67 4.03 3.88 4.58 4.47 4.04 3.62 3.59 3.82 3.63 3.75 2.80 2.56 3.64 3.37 3.41 3.59 3.64 3.80 4.31
Zoetis Inc. 3.47 2.77 2.63 4.39 4.17 4.05 3.60 4.06 4.38 4.27 3.85 2.80 2.01 1.96 3.03 3.24 3.20 2.84 2.15 2.08 2.11 2.27

Based on: 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-08-01), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-13), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-10-30), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-10-31), 10-Q (filing date: 2016-08-01), 10-Q (filing date: 2016-05-03), 10-K (filing date: 2016-02-16), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-04).

1 Q2 2020 Calculation
Current ratio = Current assets ÷ Current liabilities
= 6,694,320 ÷ 1,798,640 = 3.72

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Vertex Pharmaceuticals Inc.’s current ratio deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level.

Quick Ratio

Vertex Pharmaceuticals Inc., quick ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 4,831,332  3,593,412  3,109,322  3,397,941  3,294,684  2,893,885  2,650,134  2,478,302  2,145,359  1,995,893  1,665,412  1,384,966  1,223,130  1,003,679  1,183,945  719,692  605,866  604,245  714,768  756,250  870,543  664,879 
Marketable securities 619,437  596,984  698,972  598,390  656,538  584,150  518,108  577,583  622,396  481,124  423,254  427,282  445,520  405,103  250,612  408,749  465,570  421,373  327,694  249,580  145,907  516,255 
Accounts receivable, net 791,768  845,269  633,518  443,315  464,900  438,297  409,688  379,755  393,439  327,294  281,343  263,493  247,949  207,955  201,083  182,229  189,356  181,878  177,639  165,272  94,519  80,332 
Total quick assets 6,242,537  5,035,665  4,441,812  4,439,646  4,416,122  3,916,332  3,577,930  3,435,640  3,161,194  2,804,311  2,370,009  2,075,741  1,916,599  1,616,737  1,635,640  1,310,670  1,260,792  1,207,496  1,220,101  1,171,102  1,110,969  1,261,466 
 
Current liabilities 1,798,640  1,538,750  1,334,827  1,388,894  1,259,220  1,106,468  1,120,292  992,508  927,300  827,312  807,260  710,739  625,406  489,796  792,537  722,841  622,855  552,041  506,349  374,959  373,823  302,438 
Liquidity Ratio
Quick ratio1 3.47 3.27 3.33 3.20 3.51 3.54 3.19 3.46 3.41 3.39 2.94 2.92 3.06 3.30 2.06 1.81 2.02 2.19 2.41 3.12 2.97 4.17
Benchmarks
Quick Ratio, Competitors2
Abbott Laboratories 0.93 0.83 0.88 0.93 0.98 0.94 1.03 1.00 0.94 1.04 1.67 2.02 2.13 2.01 3.31 0.94 0.92 0.88 1.04 1.10 1.60 1.45
AbbVie Inc. 0.58 2.88 2.91 0.92 0.64 0.78 0.78 0.95 0.55 0.90 0.89 1.11 0.98 1.24 1.14 1.42 1.41 1.25 1.21 1.57 1.12 1.10
Amgen Inc. 1.60 1.10 1.01 2.28 2.41 2.37 2.44 2.68 2.94 3.42 4.98 5.46 5.47 3.96 3.68 3.90 3.52 4.44 3.97 4.75 4.76 4.68
Biogen Inc. 2.00 1.39 1.43 1.57 1.70 2.07 1.83 2.19 1.79 2.67 1.78 1.62 1.49 1.57 1.94 2.44 2.16 1.91 1.93 2.84 1.57 1.98
Bristol-Myers Squibb Co. 1.26 1.38 1.26 3.63 3.61 1.64 1.39 1.31 1.18 1.29 1.37 1.38 1.36 1.37 1.35 1.24 1.30 1.22 1.07 1.30 1.23 1.44
Eli Lilly & Co. 0.68 0.64 0.68 0.66 0.67 0.65 1.20 1.36 0.96 0.87 0.91 0.94 0.92 0.78 0.98 1.06 1.00 0.98 1.04 1.01 1.01 0.95
Gilead Sciences Inc. 2.09 2.78 2.86 2.74 3.41 3.32 3.15 3.16 2.70 2.60 2.52 3.39 3.01 2.19 1.78 1.57 1.39 1.33 2.07 2.33 1.56 2.17
Illumina Inc. 3.28 3.61 6.00 5.99 5.95 3.28 2.23 2.20 2.39 2.35 3.43 3.65 3.32 2.98 2.75 3.05 3.09 3.63 2.90 3.17 2.59 2.42
Johnson & Johnson 0.92 0.98 0.94 0.93 0.95 1.01 1.08 1.22 1.17 1.08 1.04 0.92 0.91 2.06 2.04 2.25 2.54 2.32 1.77 1.93 1.87 1.80
Merck & Co. Inc. 0.84 0.66 0.78 0.80 0.75 0.88 0.72 0.95 0.82 0.86 0.83 0.97 1.03 1.13 1.24 1.31 1.26 1.13 1.04 1.05 1.02 1.09
Pfizer Inc. 0.98 0.60 0.50 0.50 0.71 0.72 0.84 0.94 0.72 0.76 0.93 0.95 0.88 0.94 0.84 0.70 0.94 0.99 1.07 1.08 1.62 1.81
Regeneron Pharmaceuticals Inc. 1.61 3.38 2.81 3.14 2.99 3.66 3.50 3.10 2.80 2.82 2.98 2.94 3.02 2.34 2.13 3.18 2.94 2.95 3.10 3.18 3.32 3.88
Zoetis Inc. 2.39 1.69 1.67 2.72 2.58 2.55 2.24 2.31 2.62 2.60 2.34 1.71 0.94 0.92 1.47 1.51 1.49 1.36 1.17 0.98 0.98 1.07

Based on: 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-08-01), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-13), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-10-30), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-10-31), 10-Q (filing date: 2016-08-01), 10-Q (filing date: 2016-05-03), 10-K (filing date: 2016-02-16), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-04).

1 Q2 2020 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 6,242,537 ÷ 1,798,640 = 3.47

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Vertex Pharmaceuticals Inc.’s quick ratio deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level.

Cash Ratio

Vertex Pharmaceuticals Inc., cash ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 4,831,332  3,593,412  3,109,322  3,397,941  3,294,684  2,893,885  2,650,134  2,478,302  2,145,359  1,995,893  1,665,412  1,384,966  1,223,130  1,003,679  1,183,945  719,692  605,866  604,245  714,768  756,250  870,543  664,879 
Marketable securities 619,437  596,984  698,972  598,390  656,538  584,150  518,108  577,583  622,396  481,124  423,254  427,282  445,520  405,103  250,612  408,749  465,570  421,373  327,694  249,580  145,907  516,255 
Total cash assets 5,450,769  4,190,396  3,808,294  3,996,331  3,951,222  3,478,035  3,168,242  3,055,885  2,767,755  2,477,017  2,088,666  1,812,248  1,668,650  1,408,782  1,434,557  1,128,441  1,071,436  1,025,618  1,042,462  1,005,830  1,016,450  1,181,134 
 
Current liabilities 1,798,640  1,538,750  1,334,827  1,388,894  1,259,220  1,106,468  1,120,292  992,508  927,300  827,312  807,260  710,739  625,406  489,796  792,537  722,841  622,855  552,041  506,349  374,959  373,823  302,438 
Liquidity Ratio
Cash ratio1 3.03 2.72 2.85 2.88 3.14 3.14 2.83 3.08 2.98 2.99 2.59 2.55 2.67 2.88 1.81 1.56 1.72 1.86 2.06 2.68 2.72 3.91
Benchmarks
Cash Ratio, Competitors2
Abbott Laboratories 0.46 0.34 0.38 0.41 0.37 0.36 0.45 0.59 0.36 0.45 1.08 1.41 1.45 1.33 2.82 0.54 0.51 0.47 0.67 0.70 1.22 1.07
AbbVie Inc. 0.25 2.50 2.56 0.61 0.32 0.38 0.47 0.57 0.22 0.56 0.59 0.73 0.59 0.71 0.66 0.87 0.86 0.81 0.77 1.05 0.74 0.72
Amgen Inc. 1.09 0.68 0.69 1.94 2.05 2.07 2.17 2.41 2.62 3.07 4.62 5.05 5.02 3.65 3.40 3.60 3.23 4.08 3.62 4.34 4.35 4.28
Biogen Inc. 1.26 0.83 0.92 1.00 0.92 1.24 1.07 1.39 1.02 1.88 1.10 1.02 0.86 0.96 1.43 1.73 1.51 1.29 1.33 2.22 0.93 1.11
Bristol-Myers Squibb Co. 0.92 0.95 0.84 3.10 3.02 0.99 0.83 0.70 0.62 0.70 0.71 0.75 0.72 0.72 0.72 0.62 0.59 0.57 0.53 0.76 0.74 0.99
Eli Lilly & Co. 0.20 0.14 0.21 0.15 0.20 0.19 0.68 0.83 0.53 0.41 0.55 0.55 0.48 0.34 0.55 0.51 0.47 0.41 0.54 0.52 0.51 0.50
Gilead Sciences Inc. 1.79 2.34 2.50 2.39 3.03 2.97 2.84 2.81 2.38 2.25 2.19 2.96 2.48 1.70 1.29 1.11 0.84 0.76 1.48 1.68 0.96 1.52
Illumina Inc. 2.93 3.16 5.13 5.11 5.18 2.91 1.95 1.95 2.06 2.01 2.88 3.07 2.78 2.47 2.21 2.44 2.45 2.79 2.27 2.47 2.08 1.92
Johnson & Johnson 0.52 0.54 0.54 0.51 0.49 0.53 0.63 0.71 0.66 0.56 0.60 0.51 0.45 1.57 1.59 1.74 1.98 1.80 1.38 1.48 1.39 1.31
Merck & Co. Inc. 0.50 0.32 0.47 0.39 0.35 0.47 0.40 0.55 0.42 0.43 0.46 0.58 0.64 0.77 0.83 0.84 0.79 0.74 0.70 0.69 0.65 0.76
Pfizer Inc. 0.70 0.31 0.26 0.25 0.40 0.39 0.59 0.59 0.42 0.42 0.66 0.60 0.53 0.59 0.57 0.41 0.65 0.68 0.79 0.74 1.25 1.37
Regeneron Pharmaceuticals Inc. 0.85 1.95 1.53 1.63 1.56 2.14 1.95 1.55 1.26 1.28 1.24 1.21 1.23 1.00 0.84 1.47 1.10 0.92 1.29 1.22 1.00 1.38
Zoetis Inc. 1.85 1.13 1.07 1.74 1.66 1.66 1.39 1.39 1.61 1.65 1.43 1.13 0.40 0.36 0.65 0.63 0.63 0.58 0.65 0.36 0.35 0.41

Based on: 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-08-01), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-13), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-10-30), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-10-31), 10-Q (filing date: 2016-08-01), 10-Q (filing date: 2016-05-03), 10-K (filing date: 2016-02-16), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-04).

1 Q2 2020 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 5,450,769 ÷ 1,798,640 = 3.03

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Vertex Pharmaceuticals Inc.’s cash ratio deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level.